1. Medtech Insight
  2. >>Business

Hindsight 20/20: Jon H. Hoem

 
• By Tina Tan

Hindsight 20/20 is a Q&A feature where medtech industry veterans share their long experience taking diverse businesses – be they start-ups or publicly-listed entities – from strength to strength and navigating through times of crises. In this installment, Jon H. Hoem, whose career in the cardiology sector spans more than two decades, explains how his thinking on building a robust clinical strategy has changed; why he believes you should never skimp on hiring talent; and advises on the difficult patches start-ups might hit and how to navigate around them, among other topics.

Hindsight 20-20

Jon H. Hoem is all heart – well, almost. During the near-30 years he has worked in the medtech industry, based largely in Europe, over two thirds of this time was spent dealing with cardiovascular technologies. Hoem cut his teeth in the early 1990s in product development at ultrasound specialist Vingmed Sound AS (later to be acquired by GE), then moved on to various senior commercial roles in MediStim Inc., developer of ultrasound imaging systems used in cardiac surgery, then atrial fibrillation treatment company AtriCure Inc.

Since 2008, Hoem has been leading start-ups like Miracor Medical Systems GMBH, which has developed a therapy to improve...

More from Business

More from Medtech Insight

Experts Call For Database Of Medical Device Labels

 
• By Elizabeth Orr

A recent JAMA column called for the US FDA to create an online database of medical device labeling, arguing that the move would increase transparency and help researchers, among other benefits. Medtech Insight discussed the idea with the paper’s lead author.

Execs On The Move: July 7–11, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 
• By Amanda Maxwell

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.